TRANSGENE
BIOTEK LIMITED
INNOVATING. FOR LIFE.

February 3, 2026

General Manager
Department of Surveillance & Supervision
BSE Limited, 25th Floor, P. J. Towers
Dalal Street
Mumbai – 400 001

Dear Sir,

Subject: Declaration under Clause 36 of Listing Agreement with BSE
PROHIBITORY ORDER NO. RRD/SR0/1166/2026/1 – SEBI

In compliance to the terms of Clause 36 of listing agreement, we wish to bring to the notice of investors that we received a letter from the Recovery Officer, Securities and Exchange Board of India, Southern Regional Office, Chennai dated 19th January 2026 intimating about the Order under Rule 16 and 48 of the Second Schedule to the Income-tax Act, 1961 read with Section 28A of the Securities and Exchange Board of India Act, 1992 wherein Recovery proceedings against our company, Transgene Biotek Limited have been initiated for failure to pay the penalty of Rs.38 lacs pertaining to the SEBI Adjudication order dated 27th June 2022. This order and its inherent paralyzing actions are said to have been initiated in spite of our intimation about our appeal to the Securities Appellate Tribunal at Mumbai AT on October 7, 2022, challenging this order and this appeal still remaining to be disposed.

The order contained prohibiting the company from disposing, transferring, alienating, or charging all the immovable properties and movable properties held by the company apart from freezing the bank accounts in addition to the imposition of penal interests for the delay in paying the penalty amount. As a consequence to the above-mentioned act of freezing of all accounts, payments on various accounts including salaries to the employees have been paralyzed bringing all activities to a standstill.

Kind regards

Dr. K. Koteswara Rao
Managing Director